Sheila Gujrathi

Chair
Ventyx, ADARx, ImmPACT Bio

Dr. Gujrathi is cofounder and former CEO of Gossamer Bio, which is discovering and developing a clinical and research pipeline of novel therapeutics for immunology, inflammation, and oncology. She serves as Chair of the BOD of ADARx Pharmaceuticals, previously serving as Chair of the BOD of Turning Point Therapeutics and on the BOD at Five Prime Therapeutics (acquired by Amgen) and Ambrx. (acquired by a consortium of investors). Dr. Gujrathi is an E&Y Entrepreneur of the Year awardee. Dr. Gujrathi served as CMO of Receptos (acquired by Celgene). At Receptos, she built the development, regulatory and quality organizations and advanced the pipeline of drug candidates, including Zeposia®, which is approved for multiple sclerosis and for ulcerative colitis. Dr. Gujrathi was VP of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb, where she led late-stage clinical development and supported numerous global regulatory filings and approvals for Orencia® and Nulojix®. She was responsible for development of other assets in the BMS immunology clinical pipeline and advised the strategies for discovery, early development, and external business development within the immunoscience franchise. She received her MD in the accelerated Honors Program in Medical Education and her BS in biomedical engineering with highest distinction from Northwestern. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and fellowship training in allergy/immunology at UCSF and Stanford.